Oeckl, Patrick http://orcid.org/0000-0002-7652-7023
Weydt, Patrick
Thal, Dietmar R. http://orcid.org/0000-0002-1036-1075
Weishaupt, Jochen H.
Ludolph, Albert C.
Otto, Markus http://orcid.org/0000-0003-4273-4267
Funding for this research was provided by:
EU Joint Programme – Neurodegenerative Disease Research (01ED1202A, 01ED1203F, 01ED1512)
Bundesministerium für Bildung und Forschung (01GI1007A, 01GM1103A)
Horizon 2020 Framework Programme (633190)
European Commission (246513)
Deutsche Forschungsgemeinschaft (SFB1279)
Baden-Württemberg Stiftung (D.3830)
Boehringer Ingelheim Ulm University BioCenter (D.5009)
Fondation Thierry Latran
Fonds Wetenschappelijk Onderzoek (G0F8516N)
Universitaire Ziekenhuizen Leuven, KU Leuven (C14-17-107)
Article History
Received: 4 September 2019
Revised: 11 October 2019
Accepted: 1 November 2019
First Online: 7 November 2019
Compliance with ethical standards
:
: PO, PW, JHW, ACL and MO report no conflict of interest. DRT received consultant honorary from GE-Healthcare (UK), and Covance Laboratories (UK), speaker honorary from Novartis Pharma AG (Switzerland), travel reimbursement from GE-Healthcare (UK) and UCB (Belgium) and collaborated with Novartis Pharma AG (Switzerland), Probiodrug (Germany), GE-Healthcare (UK), and Janssen Pharmaceutical Companies (Belgium).
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee (Ethics Committee of Ulm) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.